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Abstract 35 
Background: Little is known about the use of antibiotics and the extent of AAD in 36 
spinal cord injury (SCI) patients.  37 
Aims: Our aim was to (1)record the use of antibiotics; (2)establish the prevalence of 38 
AAD and Clostridium difficile infection (CDI) and; (3)assess if there was any 39 
seasonal variation in antibiotic use and incidence of AAD. 40 
Methods: A retrospective study was conducted in six European SCI centres during 41 
October 2014 to June 2015. We define AAD as 2 or more watery stools type 5, 6 or 7 42 
(Bristol stool scale) over 24-hours. 43 
Findings: One-thousand-two-hundred-and-sixty-seven adults (median age: 54 years, 44 
30.7% female) with SCI (52.7% tetraplegia; 59% complete SCI) were included. Of 45 
215 (17%) patients on antibiotics, the top three indications for antibiotics were 46 
urinary-tract infections, infected pressure ulcers and other skin-infections. Thirty-two 47 
of 215 (14.9%) developed AAD and two of 1267 (0.16%) developed CDI. AAD was 48 
more common in summer season than in spring, autumn and winter. 49 
(30.3%,3.8%,7.4%,16.9%, p<0.01). AAD was associated with adults age above 65-50 
years, tetraplegia, higher body-mass-index, hypoalbuminaemia, polypharmacy, 51 
multiple antibiotic users and high-risk antibiotic use. The summer and winter season 52 
and male gender were identified as independent predictors for AAD.  53 
Conclusion: This study found AAD is common in SCI patients and UTI is the most 54 
common cause of infection. Summer and winter seasons and male gender were unique 55 
predictor for AAD. Both AAD and UTI are potentially preventable, thus further work 56 
should focus on preventing the over-use of antibiotics and strategies in improving 57 
hospital infection control measures.  58 
 59 
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3 
Introduction 69 
Antibiotic associated diarrhoea (AAD) is a common complication of antibiotic 70 
treatment. The disturbance of normal gut microbiota, especially after antibiotic use, is 71 
thought to predispose patients to pathogenic bacterial colonisation
1,2
  Of bacterial 72 
causes, it is reported that three predominantly opportunistic pathogens including 73 
Clostridium difficile (C. diff), Staphylococcus aureus and Clostridium perfringens are  74 
associated with AAD
3
. AAD is described as unexplained diarrhoea that occurs in 75 
association with antibiotic administration.
3
 Diarrhoea is thought to be clinically 76 
significant if there are more than 3 loose stools per day
4,5
 although a recent survey in 77 
SCI centres found the definition of diarrhoea and diagnostic criteria of C. diff 78 
infection (CDI) vary among spinal cord injury (SCI) centres.
6
 In addition, diarrhoea 79 
after SCI is often complicated by spurious diarrhoea due to underlying constipation.80 
  81 
AAD occurs in about 5-25% of adult patients upon administration of 82 
antibiotics.
4
 CDI occurs most often as a consequence of disruption of the gut 83 
microbiota following broad spectrum antibiotics. CDI accounts for 20-30% of AAD, 84 
although some estimates are more conservative.
3,7
 In the majority of patients, full 85 
recovery is usual, although particularly older and frail patients may suffer loss of 86 
dignity, become seriously ill with dehydration as a consequence of the diarrhoea, and 87 
may progress to develop life threatening pseudomembranous colitis.  88 
 89 
Exposure to antibiotics within the previous three months is thought to be one 90 
of the most important risk factors for developing CDI. Literature reported  risk factors 91 
include age
9,8,10
, recurrent antibiotic use
8,10
, hospitalisation
9
, severity of underlying 92 
illness
9
, use of proton pump inhibitors (PPI)
9,10,11
and malnutrition 
12,13
 Seasonal 93 
variation
12,14,15
 of CDI has been noted, however, this may not be a characteristic that 94 
is shared among all patient groups.
16
 SCI patients are at higher risk of hospital 95 
acquired infections because of longer hospital stay for acute and rehabilitation stay.
16
 96 
Newly-injured SCI patients require anticoagulation therapy to prevent venous 97 
thromboembolism. This increases the risk of gastric ulcers, therefore patients 98 
commonly receive a PPI to protect the stomach against this adverse effect. Literature 99 
reports show that patients on PPIs have a relative risk of 69% of contracting C. diff 100 
against patients who are not taking the medication.
17
  In addition, increased use of 101 
invasive devices such as urinary catheters increase the risks of antibiotic use, thus 102 
4 
CDIs.
16 ,18 
In SCI, AAD / CDI can contribute to or complicate any pressure ulcer 103 
management as it leads to moisture and bacteria that could potentially contaminate 104 
pressure ulcers. Recurrent diarrhoea also depletes the body of electrolytes which are 105 
key in wound healing such as potassium, or during chronic episode micronutrients 106 
such as magnesium and zinc.
14
 This is through direct loss, but also via malabsorption. 107 
Diarrhoea causes dehydration and malnutrition with further medical consequences.
19
 
 
108 
 109 
The objectives of this study were to (1) record the use of antibiotics (2) 110 
establish the prevalence of AAD and CDI and (3) assess if there is any seasonal 111 
variation in infections and prevalence of AAD in six international SCI centres. 112 
 113 
Methods 114 
This was a one year, retrospective, point-prevalence study. The data was 115 
collected from six European SCI centres on four different dates, during the period 116 
October 2014 to June 2015. In order to analyse the seasonal variation of AAD, CDI 117 
and infections caused, we collected  data from all in-patients on 4 different time 118 
points: (1) 1
st
 October 2014 (Autumn), (2) 1
st
 February 2015(Winter), (3) 6
th
 April 119 
2015 (Spring), and (4) 1
st
 June 2015 (Summer). For those SCI centre with fewer than 120 
25 beds, an additional day in each season was allocated: (1) 15
th
 September 2014 121 
(Autumn), (2) 12
th
 January 2015(Winter),(3) 4
th
 March 2015(Spring), and (4) 6
th
 July 122 
2015 (Summer).  123 
 124 
A 30 item cross-sectional questionnaire was distributed to the SCI centres’ clinicians. 125 
The questionnaire consisted of three sections: the first section collected individual’s 126 
baseline demographics (at the time of data collection), level and cause of SCI, 127 
presence of co-morbidities. Routine blood biochemistry and haematology data were 128 
collected +/- 3 days of study date. The second section collected the number of 129 
medications and whether patients were on antibiotics. The indication for starting 130 
antibiotics, dose, route and frequency of antibiotics, use of proton pump inhibitor, H2 131 
blocker, laxatives and anti-diarrhoeal agents were also collected. The last section was 132 
aimed at determining the occurrence of diarrhoea and C. diff infection.   133 
 134 
5 
We defined diarrhoea as 2 or more watery stools type 5, 6 or 7 (Bristol stool 135 
scale) over 24 hours.
5
  We defined AAD as 2 or more loose stools (Bristol Stool Scale 136 
type 5,6, 7) up to 7 days after finishing antibiotics.  CDI was confirmed by a positive 137 
C. difficile toxin A and B in stool samples. 138 
 139 
The survey was sent to the six SCIC’s medical lead in four western European 140 
countries with a covering letter addressed to the local SCI medical lead explaining 141 
that our investigation would be used to understand the use of antibiotics in their SCI 142 
centres. We aimed to include one SCIC for each country with 10 to 20 million 143 
inhabitants, and two for countries greater than 20 million inhabitants. Participating 144 
centres were reassured that all data would be treated anonymously.  145 
 146 
Formal ethical permission to conduct the study was not required by the 147 
Institution’s review board as it did not involving active patient participation.20 The 148 
questionnaires were approved by the local clinical audit departments. In addition, we 149 
tested the pilot questionnaire on three patients to assess the content and time required 150 
to complete the questionnaire; feedback from this guided the drafting of the final 151 
version of the questionnaire (supplementary information). Completed questionnaires 152 
were anonymised further prior to data input and analysis.  Two reminders were sent 153 
(at eight weeks and twelve weeks after the initial survey distribution). 154 
 155 
The intensity of antibiotic exposure was used to categorise patients into those 156 
on relatively low-risk antibiotics (metronidazole and parenteral aminoglycosides), 157 
those on ‘medium-risk’antibiotics (tetracyclines, sulphonamides, and macrolides) and 158 
those on ‘high-risk’ antibiotics (aminopenicillin, cephalosporins, lincosamides and 159 
quinolones), using the criteria described elsewhere.
21
  160 
 161 
Statistical analysis 162 
The prevalence of AAD and CDI was obtained by dividing the total number of 163 
patients that had developed AAD / CDI by the total number of patients studied during 164 
the study period. Descriptive statistics were used to calculate response frequency. 165 
Data was reported as mean (s.d.) or median (ranges).  Χ2 tests were used to compare 166 
differences in the distribution of qualitative variables. Differences in quantitative 167 
6 
variables, according to their distribution, were analyzed by the parametric t test or the 168 
non-parametric Mann–Whitney test. Univariate linear regression analysis of the 169 
occurrence of AAD was then undertaken. Those which were significant (p<0.05) were 170 
entered into a multivariate analysis to determine which made a significant unique 171 
contribution to AAD. As only a small number of CDI occurred, multiple binary 172 
logistic regression analysis was used to determine significant predictors for AAD, and 173 
effect estimates were presented as the OR and 95% CI. For all tests, a P value of 0·05 174 
or less or when the 95% CI for OR did not exceed 1·0 was considered as significant. 175 
Statistical analysis was performed using the Minitab statistical software (version 15.0; 176 
Minitab, Inc.) and SPSS (version 19; IBM Corporation). 177 
  178 
Approximately 35% of the routine data were missed in the present study 179 
(predominantly demographics, biochemical and hematological variables from those 180 
not on antibiotics) and approximately 10% of data were missed in those with 181 
antibiotics. To reduce the bias implicit in utilizing only complete cases, multiple 182 
imputation using SPSS (version 19; IBM Corporation, Chicago) Markov Chain Monte 183 
Carlo multiple functions were used to produce five imputed datasets. These were each 184 
analyzed as normal; thereafter, standard multiple imputation procedures were used to 185 
combine multiple scalar and multivariate estimate quantities. There was no missing 186 
data in respect of the primary end-points of the study (i.e. AAD). 187 
   188 
Results 189 
All six SCICs we approached responded to the survey. The centres contained a 190 
total of 431 SCI beds (20 in Belgium, 20 in the Netherlands, 210 in Spain and 181 in 191 
the United Kingdom. A total of 1,267 SCI (52.7% tetraplegia; 59.0% complete SCI) 192 
adults (median age: 54 years, 30.7% female) data were included in this study. No 193 
patients were excluded. 215 (17%) patients were on antibiotics; the top five 194 
indications for antibiotics were urinary tract infections (n=82, 36.7%), pressure ulcers 195 
/ wound infections (n=45, 19.9%), other skin infection (n=17, 12.4%), chest infection 196 
(n=21, 9.3%) and osteomyelitis (n=18, 7.5%). (Table I) Urinary tract infections were 197 
found to be more common in the autumn season (55.6%) when compared with winter 198 
(33.9%), spring (35.7%) and summer (33.9%), respectively (p=0.021). (Table I) 199 
 200 
7 
Thirty-two of 215 patients on antibiotics (14.9%) developed diarrhoea (AAD). 201 
This is significantly higher when compared to those not on antibiotics (6.4% of whom 202 
developed diarrhoea, p<0.01). (Table II) Patients who received antibiotics tended to 203 
take more medication (13 v 10, p<0.01), be paraplegic (57.7% v 45.1%, p<0.01), have 204 
incomplete SCI (57.8% v 34.8%, p<0.01), have a higher c-reactive protein (mg/L: 21 205 
v 12, p<0.01) and be re-admissions (37.7% v 20.1%, p<0.01). (Table II) No 206 
significant difference was found in the number of older adults, serum albumin level, 207 
body mass index, mean white cell counts, proportions of patients using proton pump 208 
inhibitor, H2 blocker, laxatives (single and multiple) and anti-diarrhoeal agents. 209 
(Table II)  210 
 211 
The centres’ antibiotic usage, percentage of antibiotic use, prevalence of AAD 212 
and CDI were varied. Table III. Overall UK SCI centres (apart from centre 5) use 213 
more antibiotics than non-UK centres (21.8% v 17%, p=0.035). There was no 214 
statistical significant difference in the occurrence of AAD in UK and non-UK SCI 215 
patients. However, there was a statistical significant difference on the occurrence of 216 
AAD amongst UK centres (24.2%, 8.7%, 6.5%, p=0.036) and non-UK centres (5.6%, 217 
41.2%, 0%, p<0.01). 218 
 219 
Overall, AAD was not significantly associated with longer duration of 220 
antibiotic therapy (mean duration, 16 days for patients with AAD vs 10 days for those 221 
without AAD, p=0.322). (Table 3) 32.4% patients received multiple antibiotics. 222 
Patients tended to develop AAD if they were on multiple antibiotics (50% in patients 223 
with AAD vs 29.9% for those without AAD, p=0.041). The most frequently used 224 
antibiotics regimens that were associated with AAD were piperacillin / tazobactam, 225 
clindamycin and flucoxacillin. 31.3% of patients that had developed AAD were found 226 
to be on high-risk antibiotics compared to 15.2% of patients on low-risk antibiotics, 227 
p=0.041. (Table IV) 228 
 229 
AAD was more common in the summer season when compared to spring, 230 
autumn and winter. (30.3%, 3.8%, 7.4%, 16.9%, p<0.01). (Table. 1) AAD was 231 
associated with older adults aged 65 years or above (54.8% v 18.1%, p<0.01), 232 
tetraplegia (68.7% v 38.2%, p<0.01) and higher body mass index: 28.2 v 25.7, 233 
8 
p<0.01). In addition, patients with AAD tended to have a lower serum albumin level 234 
(28g/L v 34g/L, p<0.001), receive more medications (14 v 11, p<0.01), H2 blocker 235 
user (21.9% v 5.4%, p<0.01), multiple antibiotics (50% v 29.9%, p=0.041) and use 236 
high-risk antibiotics (31.4% v 15.2%, p=0.041). 237 
 238 
The binary multivariate logistic regression analysis identified summer season 239 
(OR 7.77, 95% CI 1.49, 40.7), winter season (OR 6.0, 95% CI 1.1, 33.7), adult age 240 
greater than 65 years old (IR 3.22, 95% CI 1.27, 8.18) and being male (OR: 5.34, 95% 241 
CI 1.2, 23.7) as the unique risk factors for AAD.  (Table V) 242 
 243 
As only a small number of patients developed CDI (n=2), this form of analysis 244 
was deemed inappropriate for the CDI data. 245 
 246 
Discussion 247 
The purpose of this study was to establish the prevalence and assess whether seasonal 248 
variation affects the occurrence of AAD and CDI among SCI patients. The prevalence 249 
of AAD was 14.9% and CDI was 0.24%.  This is comparable with the reported 250 
prevalence of AAD
3
 and CDI
7
 in general populations and previous studies conducted 251 
in SCI centres.
19, 22
 Our study found that summer and winter seasons and male gender 252 
are unique risk factors for AAD.   253 
 254 
 The prevalence of AAD varied between SCI centres, this could be due to non-255 
standardised infection prevention and control and antimicrobial stewardship 256 
practices
6
. In addition some SCI centres may have a different threshold for use of 257 
antibiotics as they may be part of general hospitals which have Trauma centres and / 258 
or Emergency Departments (therefore a higher chance of prescribing antibiotics after 259 
trauma and spinal surgery) when compared to some centres just admitting elective 260 
admissions from other  general hospitals.  261 
 262 
Antibiotic administration causes an alternation in intestinal microbiota, which 263 
results in the loss of physiologic processes involving the metabolism of nutrients. 264 
Multiple antibiotics have been implicated in reduced colonic bacterial carbohydrate 265 
metabolism. Clindamycin has been shown in vitro to decrease faecal carbohydrate 266 
metabolism as well as concentrations of SCFA. Our data found that a significant 267 
9 
higher proportion of patients that developed AAD were on higher-risk antibiotics and 268 
this is comparable to previous reports.
21
  269 
 
 
270 
The present study found the prevalence of CDI was low in comparison to 271 
previous reports. 
13,14,15
 The fall in CDI prevalence reflects the continuing year-on-272 
year fall of overall Clostridium difficile infection cases in British hospitals. Indeed, 273 
the overall CDI rate for England in the UK has fallen from 148.7 cases per 100,000 in 274 
2007/8 to 40.8 per 100,000 in 2015/6.
24
 In addition, the low prevalence of CDI could 275 
be due to the variation in AAD and CDI definition amongst SCI centres 
25
, short study 276 
time period and point prevalence nature of the study. However, the surprisingly low 277 
CDI in our European centres (0% in all 3 centres) may be due to being under-278 
diagnosed as they lack established CDI surveillance systems.
26
  279 
 280 
Due to the limited number of CDI cases (n=2) in the present study, we were 281 
not able to analyse potential risk factors for CDI but, apart from the traditional risk 282 
factors, our study found summer season and polypharmacy may be additional risk 283 
factors for AAD.   284 
 285 
Strengths and limitations 286 
The main strength of this study is that it is the first official international study 287 
conducted in a multicenter European setting which has a large sample size (n=1,267). 288 
It also includes a mixture of various sized centres from both centres admitting elective 289 
and emergency patients immediately after SCI, therefore this study allows inter-centre 290 
comparison.   291 
 292 
This study has some limitations. Firstly, some large centres may be over-293 
represented in the results. To tackle this, we instructed an additional data collection 294 
date for centres having fewer than 25 beds. Secondly, the present study did not judge 295 
whether the use of antibiotics was appropriately prescribed, therefore it may 296 
overestimate the use of antibiotics especially in centres without established antibiotic 297 
stewardship. The selection of the SCIC was at the discretion of the study authors, 298 
however, the SCI centres represented approximately 15-20% of the SCIC’s beds in the 299 
UK, Belgium, the Netherlands and Spain.  Therefore, results derived from this sample 300 
10 
of SCICs could be considered representative. Thirdly, we defined the follow up period as 301 
7-days after their initial course of antibiotics is finished. However, we acknowledge that 302 
AAD/ CDI may occur up to three months after the initial exposure of antibiotics.
27
 In order to 303 
assess the risk factor of AAD / CDI in SCI patients, we recommended a further study to 304 
include the history of antibiotic use in the previous three months and a longer follow up 305 
period is warranted. Finally, different SCI centres may have different policies on 306 
antibiotic prescribing and different catheter and bowel management programmes. 307 
Previous research has found different definitions of diarrhoea have been used in 308 
different SCICs in the UK and other European SCI centres.
6
 Indeed, to use a 309 
standardised definition of diarrhoea would not just help in identifying and treating 310 
patients with diarrhoea but also allowing bench-marking with other SCI centres to 311 
strengthen future AAD / CDI research.  312 
 313 
Conclusions 314 
Our study indicates CDI is a relatively uncommon occurrence in SCI patients, despite 315 
antibiotic use being relatively common in SCI patients, and diarrhoea being associated 316 
with antibiotic use. UTI is the most common cause of infection in this group of 317 
patients and  efforts to prevent this will significantly reduce the numbers of antibiotic 318 
courses prescribed. Further studies should focus on whether AAD is associated with 319 
adverse clinical outcomes such as longer hospital stay and/or prolonged rehabilitation. 320 
As both UTI and AAD are potentially preventable, additional focus on implementing 321 
standardized infection control practice / surveillance systems across SCI centres and 322 
improving antimicrobial stewardship could reduce the incidence of UTI and AAD, 323 
especially in summer and winter seasons.    324 
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Table I. Summary of infections in SCICs by seasons 359 
     All  Spring  Summer Autumn Winter  P-value 360 
Total no. of patients    1267  n=345  n=355  n=342  n=338 361 
Urinary tract infection*   82, 36.7% 15, 35.7% 19, 33.9% 30, 55.6% 18, 33.9% 0.021 362 
Pressure ulcers / wound infection  45, 19.9% 15, 28.8% 11, 19.6% 9, 16.7% 10, 18.9% 0.431 363 
Skin infection    17, 12.4% 6, 11.5% 4, 7.1%  3, 5.6%  4, 7.5%  0.704 364 
Chest infection    21,   9.3% 3, 5.8%  6, 10.7% 7, 12.9% 5, 9.4%  0.652 365 
Osteomyelitis    18,   7.5% 6, 11.5% 7, 12.5% 2, 3.7%  3, 5.7%  0.265 366 
Spinal metal work infection  11,   4.9% 2, 3.8%  5, 8.9%  1, 1.9%  3, 5.7%  0.381 367 
Gall bladder infection   7,   3.1% 2, 3.8%  0, 0%  0, 0%  5, 9.4%  - 368 
Infected cysts    4,   1.8% 1, 1.9%  0, 0%  1, 1.9%  2, 3.8%  - 369 
Eye infection    3,   1.3% 2, 3.8%  1, 1.8%  0, 0%  0, 0%  - 370 
Nail infection    2,   0.9% 0, 0%  2, 3.6%  0, 0%  0, 0%  - 371 
Sepsis     2,   0.9% 0, 0%  1, 1.8%  0, 0%  1, 1.9%  - 372 
Ear infection    1,   0.4% 0, 0%  0, 0%  0, 0%  1, 1.9%  - 373 
Spinal TB    2,   0.9% 0, 0%  0, 0%  1, 1.9%  1, 1.9%  - 374 
Total no. of infections   215, 17.8% 52, 15.1% 56, 16.7% 54, 15.8% 53, 15.7% 0.992 375 
     376 
AAD †    32, 14.9% 2, 3.8%  17, 30.3% 4, 7.4%  9, 16.9% p<0.01  377 
CDAD     4, 0.24% 0, 0%  0, 0%  1, 0.3%  1, 0.3%  - 378 
 379 
* p <0.05; † p<0.01; AAD: antibiotic associated diarrhoea; CDAD: Clostridium difficile associated diarrhoea; *** Less than 5 case, no statistic test performed 380 
** n=37 patients were prescribed antibiotic as prophylaxis; some data inconsistent / change e.g. nail infection was due to f/u review to confirm indication of infection.   381 
13 
Table II Baseline characteristics of the study participants (Number of patients and percentages or median values) 382 
     Overall   On antibiotics   Not on antibiotics   P-value 383 
Parameters 384 
No. of diarrhoea†   61 out of 685 (8.9%) 32 out of 215 (14.9%)  29 out of 448 (6.4%)   <0.001  385 
No. of C. diff infection    4 out of 685 (0.6%) 1 out of 237 (1.3%)  3 out of 448 (0.7%)   ns 386 
Median no. of drugs†   10 (range: 1-28)  13    10     <0.001   387 
No. of patient > 65 years   176 out of 685 (25.6%) 54 out of 234 (23.1%)  122 out of 448 (27.2%)   0.269 388 
Median age    54 (range: 18-91)  59    55     0.871 389 
No. of cervical SCI†   344 out of 680 (50.5%) 100 out of 236 (42.3%)  244 out of 444 (54.9%)   0.002 390 
No. of complete SCI (AIS: A) †  386 out of 673 (57.4%) 97 out of 230 (42.2%)  289 out of 443 (65.2%)   <0.001 391 
Median body mass index (Kg/m
2
)  28.9   26.6    25     0.060 392 
No. of overweight (BMI>25 kg/m
2
)  239 out of 456(52.4%) 70 out of 121 (57.9%)  169 out of 335 (50.4%)   0.169 393 
Median of albumin (g/L) *   34   33    34     0.435 394 
Median C-reactive protein (mg/L) † 13   21    12     <0.001 395 
Median white cell counts (10
9
/L)  7.2   7.6    7.5     0.734 396 
No. of proton pump inhibitor*  342 out of 620 (55.1%) 144 out of 236 (61.0%)  198 out of 384 (51.5%)   0.025 397 
No. of H2 blocker    56 out of 612 (9.2%) 18 out of 234 (7.7%)  38 out of 378 (10.1%)   0.387 398 
No. of patient on laxatives   539 out of 618 (87.2%) 198 out of 235 (84.3%)  341 out of 383 (89.0%)   0.106 399 
No. of multiple laxatives   409 out of 539 (75.8%) 142 out of 198(71.7%)  267 out of 341 (78.3%)   0.077 400 
No. of anti-diarrhoeal agents  9 out of 602 (1.5%) 6 out of 227 (2.6%)  3 out of 375 (0.8%)   0.088 401 
No. of new admission†   504 out of 683 (73.7%) 147 out of 236 (62.3%)  357 out of 447 (79.9%)   <.0001 402 
 403 
AAD: antibiotic associated diarrhoea; GDH: glutamate dehydrogenase;  CDAD: clostridium difficile associated diarrhoea; IV: intravenous; SCI: spinal cord injury; AIS: American Spinal Injury 404 
Association Impairment Scale 405 
 406 
^^ We only reported available / returned case, especially for those not-on antibiotics 407 
* p <0.05; † p<0.01 408 
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Table III Centre’s antibiotic usage, prevalence of antibiotic associated diarrhoea (AAD) and Clostridium difficile associated diarrhoea (CDAD) 409 
 410 
Centre No. of patients No. of antibiotics % of antibiotics No. of AAD (%) CDAD 
UK centre 1 261 70 26.8 17/70, 24.2% 1/70, 1.4% 
UK centre 2 177 23 12.9 2/23, 8.7% 0/23 
UK centre 3 129 31 24 2/31, 6.5% 0/31 
Non-UK centre 4 571 90 15.8% 5/90, 5.6% 0/90 
Non-UK centre 5 49 17 34.7 7/17, 41.2% 0/17 
Non-UK centre 6 45 6 13.3 0/6 0/6 
      
UK total 567 124 21.8 21/124, 16.9% 1/124, 0.81% 
      
Non-UK total 665 113 17.0 12/ 113, 10.6% 0/113, 0% 
      
Overall 1232 237 19.2 33/237, 13.9% 1/237, 0.42% 
 411 
1. UK SCI patients seems to receive more antibiotic than in non-UK SCI patients. 21.8% v 17%, p=0.0353 412 
2. No statistical significant difference between the occurrence of AAD in UK and non-UK population. 413 
3. There is a statistical significant difference between UK centres in occurrence of AAD, 24.2% v 8.7% v 6.5%, p=0.036 414 
4. There is a statistical significant difference between non-UK centres in AAD, 5.6% v 41.2% v 0%, p<0.001 415 
15 
Table IV Baseline characteristics of the study participants on antibiotics (Number of patients and percentages or median values) 416 
     Developed AAD   Did not developed AAD    P-value 417 
      418 
Parameters 419 
No. of patient > 65 years†   17 out of 31 (54.8%)  37 out of 204 (18.1%)    <0.01 420 
No. of cervical SCI†   22 out of 32 (68.7%)  78 out of 204 (38.2%)    <0.01 421 
No. of complete SCI (AIS: A)  21 out of 32 (65.6%)  113 out of 199 (56.8%)    0.441 422 
Median body mass index (Kg/m
2
) † 28.8    25.7      <0.01 423 
Median serum albumin (g/L) †  28    34.0      <0.01 424 
No. of hypoalbuminaemia (<30g/L) * 14 out of 26 (53.8%)  49 out of 181 (27.1%)    0.011 425 
No. of drugs†    14    11      <0.01 426 
No. of proton pump inhibitor  15 out of 32 (46.9%)  129 out of 204 (63.2%)    0.083 427 
No. of H2 blocker †   7 out of 32 (21.9%)  11 out of 202 (5.4%)    <0.01 428 
No. of patient on laxatives   25 out of 32 (78.1%)  173 out of 203 (85.2%)    0.302 429 
No. of multiple laxatives   17 out of 25 (68.0%)  125 out of 173 (72.3%)    0.641 430 
No. of anti-diarrhoeal agents  2 out of 31 (6.5%)  4 out of 196 (2%)     0.191 431 
No. of new admission   17 out of 32 (53.1%)  130 out of 204 (63.7%)    0.327 432 
Median onset of SCI (days)  501    365      0.267 433 
Duration of antibiotics   16    10      0.322 434 
No. of multiple antibiotics *  16 out of 32 (50.0%)  61 out of 204 (29.9%)    0.041 435 
No. of high-risk antibiotics †  15 out of 32 (46.9%)  48 out of 204 (23.5%)    <0.01 436 
 437 
AAD: antibiotic associated diarrhoea; CDAD: clostridium difficile associated diarrhoea; IV: intravenous; SCI: spinal cord injury; AIS: American Spinal Injury Association Impairment Scale 438 
* p <0.05; † p<0.01 439 
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Table V. Multivariate logistic regression analysis to identify risk factors for antibiotics associated diarrhoea  440 
(Standard errors, odds ratios and 95% confidence intervals) 441 
 442 
 443 
Variable   SE   OR   95% CI    p-value 444 
 445 
Seasons (spring reference) 446 
 447 
Summer   0.844    7.77  1.49, 40.7   0.015 448 
Autumn   0.961    1.84  0.28, 12.1   0.525 449 
Winter    0.881    6.00  1.07, 33.7   0.042 450 
 451 
Female gender   0.775    0.18  0.04, 0.81   0.026 452 
 453 
Age >65 years old  0.475    3.22  1.27, 8.17   0.014 454 
 455 
No. of antibiotics  0.325    1.23  0.65, 2.31   0.535 456 
 457 
No. of drug   0.051    1.09  0.99, 1.21   0.070 458 
 459 
Tetraplegia   0.469    0.48  0.19, 1.21   0.120 460 
 461 
Use of H2 blocker  0.639    0.33  0.09, 1.15   0.083 462 
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